Corporate Counsel, in partnership with ALM Intelligence, on Monday released its 2025 General Counsel Report, an exclusive ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis. The consensus rating ...

Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

A star of early pandemic days, Moderna not only won in the area of earnings but also in the area of stock performance. Moderna stock soared more than 2,000% from the start of 2020 to its peak in ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna has a broad pipeline of candidates across therapeutic areas, the company ...

The S&P 500 ticked 0.1% on Monday, July 14, 2025, as trade policy remained in the spotlight to kick off a week that also ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.